Beam Therapeutics Inc. (BEAM): Price and Financial Metrics
GET POWR RATINGS... FREE!
BEAM POWR Grades
- BEAM scores best on the Stability dimension, with a Stability rank ahead of 39.91% of US stocks.
- The strongest trend for BEAM is in Growth, which has been heading up over the past 169 days.
- BEAM ranks lowest in Sentiment; there it ranks in the 1st percentile.
BEAM Stock Summary
- Beam Therapeutics Inc's stock had its IPO on February 6, 2020, making it an older stock than merely 1.27% of US equities in our set.
- With a price/sales ratio of 307,536.5, Beam Therapeutics Inc has a higher such ratio than 100% of stocks in our set.
- With a year-over-year growth in debt of 282.07%, Beam Therapeutics Inc's debt growth rate surpasses 96.34% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Beam Therapeutics Inc are ARNA, BLU, OCGN, NYMX, and INMB.
- BEAM's SEC filings can be seen here. And to visit Beam Therapeutics Inc's official web site, go to www.beamtx.com.
BEAM Price Target
For more insight on analysts targets of BEAM, see our BEAM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $93.67 | Average Broker Recommendation | 1.56 (Moderate Buy) |
BEAM Stock Price Chart Interactive Chart >
BEAM Price/Volume Stats
| Current price | $86.48 | 52-week high | $126.90 |
| Prev. close | $88.46 | 52-week low | $18.76 |
| Day low | $84.35 | Volume | 59,823 |
| Day high | $86.48 | Avg. volume | 963,325 |
| 50-day MA | $76.41 | Dividend yield | N/A |
| 200-day MA | $67.92 | Market Cap | 5.41B |
Beam Therapeutics Inc. (BEAM) Company Bio
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Latest BEAM News From Around the Web
Below are the latest news stories about Beam Therapeutics Inc that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
The 7 Best Cryptos to Buy for PrivacyCryptos are one of the hottest investment trends right now, but not everyone makes the cut on the privacy end due to regulatory pressure. |
2 Winners for a Drug Development Future That Looks Nothing Like the PastIn hindsight, the pandemic may have been that turning point for gene-based medicine. The authorization of the first vaccines using messenger RNA validated a segment of the life sciences industry that seemed destined for some futuristic version of healthcare. Genome sequencing and gene editing have been around for several years. |
Beam Therapeutics: INDs This YearPhoto by BlackJack3D/E+ via Getty Images Last time we saw, Beam Therapeutics (BEAM) was planning a "wave" of INDs beginning in 2021. Now that we are in the middle of 2021, we want to see what they have been up to. Beam Therapeutics, if you recall, is a $4.4bn recent... |
Beam Therapeutics Is Ready to Beam HigherBeam Therapeutics is pioneering the use of base editing - a potential new class of precision genetic medicines. This is way above my pay grade so let's look at the charts of BEAM. In this daily bar chart of BEAM, below, we can see that prices made a base in the $20-$30 area before rallying to a high in February above $120. |
Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare ConferenceCAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:30 a.m. ET. |
BEAM Price Returns
| 1-mo | 25.06% |
| 3-mo | -2.68% |
| 6-mo | 19.53% |
| 1-year | 220.30% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 5.93% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...